Inclusion Criteria:

          -  Patients with advanced or metastatic cancer that is refractory to standard therapy,
             relapsed after standard therapy, or have no standard therapy that induces a complete
             response of at least 10% or improves survival by at least three months; in addition,
             patients with disease that are "benign" by pathology, but relentlessly progressive,
             leading to disability, pain, and premature death in the majority of cases (including,
             but not limited to lymphangioleiomyomatosis [LAM], type 2 neurofibromatosis [NF],
             Erdheim Chester disease, and Castleman's disease) may also be considered for
             enrollment

          -  Patients should be at least four weeks from the last day of therapeutic radiation or
             cytotoxic chemotherapy or from antibody therapy, or at least five half-lives from
             non-cytotoxic targeted or biologic therapy; patients may have received palliative
             radiation immediately before (or during) treatment provided radiation is not to the
             only target lesion available

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2

          -  Karnofsky >= 60%

          -  Lansky performance status of >= 60% for participants 16 years old or younger

          -  Absolute neutrophil count >= 1,000/mL

          -  Platelets >= 50,000/mL

          -  Creatinine =< 3 X upper limit of normal (ULN)

          -  Total bilirubin =< 3.0

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 5 X ULN

          -  Fasting level of total cholesterol of no more than 350 mg/dL

          -  Triglyceride level of no more than 400 mg/dL

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry, for
             the duration of study participation, and for 90 days after the last dose

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Patients may not be receiving any other investigational agents and/or any other
             concurrent anticancer agents or therapies

        Exclusion Criteria:

          -  Patients with clinically significant unexplained bleeding within 28 days prior to
             entering the study

          -  Uncontrolled systemic vascular hypertension (systolic blood pressure > 140 mmHg,
             diastolic blood pressure > 90 mmHg on medication)

          -  Patients with clinically significant cardiovascular disease: History of CVA
             (cerebrovascular accident) within 6 months, myocardial infarction or unstable angina
             within 6 months, unstable angina pectoris

          -  Pregnant or breast-feeding women

          -  History of hypersensitivity to bevacizumab, murine products, or any component of the
             formulation

          -  History of hypersensitivity to temsirolimus or its metabolites (including sirolimus),
             polysorbate 80, or to any component of the formulation

          -  History of hypersensitivity to cetuximab, murine products, or any component of the
             formulation

          -  Patients that are taking cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4)
             inducers and/or inhibitors; if a patient has a history of taking CYP3A4 inducers
             and/or inhibitors prior to enrollment on the protocol, it is strongly recommended that
             the patient stops the drug and waits at least 5 half-lives of said drug before
             initiating therapy on protocol

          -  Colorectal cancer patients with known v-Ki-ras2 Kirsten rat sarcoma viral oncogene
             homolog (KRAS) mutation (for the arm combining bevacizumab, temsirolimus and
             cetuximab)

          -  Patients who have had major surgery within 6 weeks of enrollment in the study